scholarly journals Rotavirus acceleration of type 1 diabetes in non-obese diabetic mice depends on type I interferon signalling

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Jessica A. Pane ◽  
Fiona E. Fleming ◽  
Kate L. Graham ◽  
Helen E. Thomas ◽  
Thomas W. H. Kay ◽  
...  
Diabetes ◽  
2014 ◽  
Vol 63 (7) ◽  
pp. 2538-2550 ◽  
Author(s):  
R. C. Ferreira ◽  
H. Guo ◽  
R. M. R. Coulson ◽  
D. J. Smyth ◽  
M. L. Pekalski ◽  
...  

2002 ◽  
Vol 227 (11) ◽  
pp. 981-988 ◽  
Author(s):  
Staley A. Brod

We have proposed a unifying hypothesis of the etiopathogenesis of autoimmunity that defines autoimmunity as a type I interferon (IFN) immunodeficiency syndrome. We have examined toxicity and potential efficacy in three phase I (type 1 diabetes, rheumatoid arthritis, multiple sclerosis) and one phase II clinical trials in multiple sclerosis. In a phase I open-label trial in type 1 diabetes, ingested IFN-α preserved residual β-cell function in recent onset patients. In a second phase I trial, treatment of rheumatoid arthritis with ingested IFN-α reduced the secretion of interleukin (IL)-1, a pro-inflammatory cytokine. In a third phase I trial in multiple sclerosis, there was a significant decrease in peripheral blood mononuclear cell IL-2 and IFN-γ production after ingesting IFN-α. In a phase II randomized, placebo-controlled, double-blind trial in multiple sclerosis, 10,000 IU ingested IFN-α significantly decreased gadolinium enhancements compared with the placebo group at month 5. Tumor necrosis factor-α and IFN-γ cytokine secretion in the 10,000 IU group at month 5 showed a significant decrease that corresponded with the effect of ingested IFN-α on decreasing gadolinium enhancements. Ingested IFN-α was not toxic in any of these clinical trials. These studies suggest that ingested IFN-α may have a potential role in the treatment of autoimmunity.


Diabetes ◽  
2013 ◽  
Vol 63 (3) ◽  
pp. 1032-1040 ◽  
Author(s):  
H. S. Quah ◽  
S. Miranda-Hernandez ◽  
A. Khoo ◽  
A. Harding ◽  
S. Fynch ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Hany M. Ibrahim ◽  
Ibrahim A. El-Elaimy ◽  
Heba M. Saad Eldien ◽  
Badr Mohamed Badr ◽  
Danny M. Rabah ◽  
...  

Elevated levels of type I interferon (IFN) during type 1 diabetes mellitus (T1D) are associated with a defective immune response. In the present study, we investigated whether blocking type I IFN signaling during streptozotocin- (STZ-) induced T1D in mice improves lymphocyte proliferation and escape from continuous apoptosis. Three groups of mice were examined: diabetic mice, type I IFN signaling-incompetent diabetic mice, and control nondiabetic mice. We first found that diabetes induction was accompanied by an elevation in the plasma levels of reactive oxygen species (ROS), hydroperoxide, malondialdehyde (MDN), and the proinflammatory cytokines IL-1α, IL-1β, IL-6, and CXCL10. Blocking type 1 IFN signaling in diabetic mice significantly decreased the levels of oxidative stress and proinflammatory cytokines. In addition, lymphocytes from diabetic mice exhibited a marked reduction in their proliferative capacity, increased apoptosis, upregulation of the exhaustion marker PD-1, and aberrant phosphorylation of STAT1, STAT2, AKT and IκB-α. Interestingly, following the blocking of type I IFN signaling in diabetic mice, the lymphocytes exhibited restored proliferative capacity, decreased apoptosis, normal expression of PD-1, and normal phosphorylation of STAT1, STAT2, AKT and IκB-α. Our data suggest that elevated levels of type I IFN during T1D trigger lymphocyte exhaustion and a defective lymphocyte-medicated immune response.


Sign in / Sign up

Export Citation Format

Share Document